Removal of the bladder, called radical cystectomy, is the preferred treatment for patients with muscle-invasive bladder cancer (MIBC) as well as for some with non-muscle-invasive bladder cancer (NMIBC ...

RARC with intracorporeal urinary diversion offers survival outcomes similar to those of open radical cystectomy, but is associated with better perioperative outcomes. Real-world data support the ...

In the past decade there has been a rapid expansion of the use of robotic assistance during surgery that involves minimally invasive approaches. In the United Kingdom, robot-assisted radical ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Close-up of surgeon team during operation in operating room. Total hospital costs related to radical cystectomy are higher in the West than in all other regions of the United States, a study suggests.

A 30-day course of prophylactic antibiotics following robot-assisted radical cystectomy significantly reduces the incidence of urinary tract infections (UTIs) and related complications, researchers ...

A patient's mental health prior to surgery can influence postoperative outcomes. Removal of the bladder, or radical cystectomy (RC), is an effective treatment for locally advanced bladder cancer, but ...

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial Purpose: To investigate ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...

Prophylactic tranexamic acid showed no reduction in blood transfusion rates in open radical cystectomy patients. The trial found no significant differences in secondary outcomes, including estimated ...